Clinical trials: Bioavailability
Healthy
A Study to Compare the Bioavailability of 300 mg Trazodone Hydrochloride Extended-release Caplets and 100 mg Trazodone Hydrochloride Immediate-release Tablets (Administered Three Times Daily)
The objective of this study was to compare the pharmacokinetic profiles of the test product, 300 mg trazodone hydrochloride (HCl) extended-release caplets (containing Contramid®), when administered as a single dose, and the…
- Trial name
- NCT01121900
- Testing
- Trazodone HCl
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Labopharm Inc.
Pain Management
A Study Comparing LTG-001 SDD Formulation To LTG-001 Crystalline Immediate Release Tablets In Healthy Participants
This is a single-center, open-label, part-randomized, crossover study in 14 healthy participants to assess the PK and safety profile of an SDD formulation of LTG-001 and two crystalline LTG-001 Instant Release tablet…
- Trial name
- NCT07341152
- Testing
- LTG-001 SDD, LTG-001 Formulation A Prototype 1, LTG-001 Formulation B Prototype 2
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Latigo Biotherapeutics
Healthy
To Demonstrate the Relative Bioavailability of Cefzil 250 mg/5 ml Cefprozil Oral Suspension Fed Conditions
To demonstrate the relative bioavailability of Cefzil 250 mg/5 ml oral suspension fed conditions.
- Trial name
- NCT00881400
- Testing
- Cefprozil 250 mg/5 ml Oral Suspension (Sandoz, Austria), Cefzil (Cefprozil) 250 mg/5 ml Oral Suspension (Bristol-Myers Squibb, USA)
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Sandoz
Cardiovascular Disease
Relative Bioavailability Study of Candesartan Cilexetil Under Fasting Conditions
This study will investigate the relative bioavailability of two candidate tablet formulations of 16 milligram (mg) Candesartan cilexetil (GW615775) compared with the reference product ATACAND™ containing 16 mg Candesartan…
- Trial name
- NCT02254447
- Testing
- Candesartan Cilexetil in formulation 1, Candesartan Cilexetil in formulation 2, ATACAND
- Where
- India
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy
An Investigation Of The Absorption And Pharmacokinetics Of Multiple Doses Of A Controlled Release Pregabalin Tablet As Compared To Multiple Doses Of The Immediate Release Pregabalin Capsule
The purpose of this study is to 1)evaluate the extent of absorption of multiple doses of a pregabalin controlled release tablet as compared to multiple doses of the pregabalin immediate release capsule, 2) evaluate the…
- Trial name
- NCT01202435
- Testing
- Pregabalin controlled release, 82.5 mg, Pregabalin immediate release, 25 mg
- Where
- Belgium
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Healthy
Tolerability and Bioavailability of the P144 Peptide Inhibitor of TGF-β1 After Topical Administration in Healthy Volunteers
Transforming growth factor-beta 1 (TGF-β1) is consistently over expressed in most fibrotic diseases and displays a variety of profibrotic effects in fibroblasts.
- Trial name
- NCT00656825
- Testing
- P144 cream
- Where
- 2 sites in Spain
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- ISDIN
Bipolar I Disorder
A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Subjects With Bipolar I Disorder
The goal of this clinical trial is to assess the safety and effects of a crystallized form of lithium, AL001, when compared to commonly used lithium carbonate in individuals diagnosed with bipolar I disorder.
- Trial name
- NCT07540338
- Testing
- AL001, Lithium carbonate
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Alzamend Neuro, Inc.
Healthy
A Study of Ixekizumab in Healthy Participants
The purpose of this study is to compare three different formulations of ixekizumab. One formulation (Reference) has been approved by the Food and Drug Administration (FDA) and two formulations (Test 1 and Test 2) have not been…
- Trial name
- NCT03848416
- Testing
- Ixekizumab
- Where
- United States
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Pharmacokinetics
Relative Bioavailability of ESK-001 Tablet Versus Liquid in Healthy Participants
This is a single-center, in-house, open-label, crossover study in 15 healthy participants.
- Trial name
- NCT05330858
- Testing
- ESK-001, Rabeprazole
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Alumis Inc
Biological Availability
Bioavailability of Omega-3 Food Supplement in Healthy Subjects
The study will evaluate the relative bioavailability of Pronovum PRF-037 and Pronovum PRF-041 with PronovaPure 150:150 EE EU and Eskimo-3 (500 mg omega-3 acid triglyceride containing 80 mg EPA and 50 mg DHA per gram oil) in…
- Trial name
- NCT02376608
- Testing
- Pronova Pure 150:500 EE EU, Pronovum PRF-037, Pronovum PRF-041
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pronova BioPharma
Bioavailability and Pharmacokinetics
To Assess Dose Proportionality and Pharmacokinetic Linearity of Saninova Tablets in Healthy Participants Under Fasting Conditions
An open-label, randomized, single dose study to assess dose proportionality and pharmacokinetic linearity in healthy participants under fasting condition.
- Trial name
- Saninova (NCT07664657)
- Testing
- Vitamin C, Vitamin B2, Astragalus Root dry extract etc
- Where
- India
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Sichuan Credit Pharmaceutical Co., Ltd.
Healthy Volunteers
A Study to Evaluate the Bioavailability of Risankizumab in Pre-filled Syringe or Auto-injector in Healthy Adult Participants
The objective of this study is to evaluate the bioavailability of risankizumab new formulation in prefilled syringe (PFS) relative to the 90 mg/mL formulation in PFS in healthy volunteers.
- Trial name
- NCT05283681
- Testing
- Risankizumab
- Where
- 2 sites in United States
- Volunteers
- 226 people, healthy volunteers welcome
- Sponsor
- AbbVie
Bioavailability
Exploratory Bioavailability of Fentanyl Sublingual Spray Under Fasting Conditions
The objective of this study is to compare the rate of absorption and bioavailability of fentanyl sublingual spray 400 mcg to fentanyl citrate 100 mcg by intramuscular injection.
- Trial name
- NCT02138396
- Testing
- Fentanyl Sublingual Spray (FSS), Fentanyl Citrate Injection (FCI), Naltrexone
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- INSYS Therapeutics Inc
Migraine Headache
Bioavailability of DHE Administered by I123 POD Device, IV Injection, and Migranal Nasal Spray in Healthy Adults
A Phase I clinical trial to compare the bioavailability of dihydroergotamine mesylate (DHE) following a single dose administration of INP104 (DHE administered by I123 Precision Olfactory Delivery (POD) Device Nasal Spray) to that…
- Trial name
- NCT03401346
- Testing
- INP104, Dihydroergotamine Mesylate (DHE), Migranal Nasal Spray
- Where
- Australia
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Impel Pharmaceuticals
Pain
A Dose Proportionality and Bioavailability Assessment of Buprenorphine Transdermal Delivery System Second Generation Patches
The purpose of this study is to obtain pharmacokinetic data for a dose proportionality and relative bioavailability assessment of 2nd generation BTDS patches compared to 1st generation BTDS patches.
- Trial name
- NCT02160067
- Testing
- Second generation BTDS patch, First generation BuTrans patch
- Where
- United Kingdom
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Mundipharma Research Limited
Relative Bioavailability, AUC
Study in Healthy Subjects to Compare the Concentrations of the Omega-3 Fatty Acids EPA and DHA in Blood When Delivered as Three New Capsules in Relation to the Epanova® Capsule Under Fasting and Fed Conditions
This study is a randomized, open-label, cross-over study in healthy subjects performed at a single study center. The study is divided into two parts, Part 1 and Part 2.
- Conditions
- Relative Bioavailability, AUC, Cmax, Pharmacokinetics
- Trial name
- NCT02359045
- Testing
- D1400147, D14000136, D14000137
- Where
- United States
- Volunteers
- 137 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Chronic Kidney Disease
Study to Assess Relative Bioavailability and Safety of AZD5718 in Healthy Volunteers
This study will be a randomised, open-label, 3-period, 3-treatment, single-dose, crossover study in healthy subjects The study will be performed at a single study centre in the United Kingdom.
- Trial name
- NCT04734275
- Testing
- AZD5718
- Where
- United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy
Effect of Meal Composition and Timing on Evobrutinib Bioavailability
This study will evaluate the Pharmacokinetics (PK) of the Phase II tablet formulation of Evobrutinib under fasted conditions, within 30 minutes after start of a light meal, one hour prior to start of a low-fat meal, and 2 hours…
- Trial name
- NCT03934502
- Testing
- Evobrutinib
- Where
- Germany
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Healthy
Anastrozole 1 mg Tablets Under Fasting Conditions
The objective of this study is to evaluate the comparative bioavailability between Anastrozole 1 mg Tablets (Teva Pharmaceuticals USA) and Arimidex® 1 mg Tablets (AstraZeneca Pharmaceuticals LP, USA), after a single-dose in…
- Trial name
- NCT01182181
- Testing
- Anastrozole (Teva Pharmaceuticals USA), Anastrozole (Arimidex®)
- Where
- Canada
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Teva Pharmaceuticals USA
Infections, Human Immunodeficiency Virus and Hepatitis
Relative Bioavailability Study of GSK1265744 Formulations
This is a single-center, randomized, open-label, balanced, 3 way crossover study (3 periods) in healthy adult subjects. During each period, subjects will receive a single dose of GSK1265744 oral formulation in the fasted state…
- Trial name
- NCT01648257
- Testing
- GSK1265744 Na Salt Tablets, GSK1265744 Free Acid Nanomilled Capsules, GSK1265744 Free Acid Micronized Capsules
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare